Get the latest news, insights, and market updates on VSTM (Verastem, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Verastem (VSTM) Upgraded to Buy: Here's Why
Verastem (VSTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Nov 3, 2025 - $VSTM
Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment
Verastem, Inc. (NASDAQ:VSTM) is one of the top long-term biotechnology stocks to buy. On October 23, Verastem, Inc. (NASDAQ:VSTM) reported positive preliminary results from an ongoing phase 1/2a dose-escalation trial of vs-7375, an oral KRAS G12D (on/off) inhibitor, in patients with KRAS G12D-mutant solid tumors. The preliminary safety and tolerability data indicate that VS-7375 can […] Oct 29, 2025 - $VSTM
Can Verastem's (VSTM) Early KRAS Results Redefine Its Position in Oncology Innovation?
Verastem Oncology recently reported encouraging preliminary results from its ongoing Phase 1/2a trial of VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor in previously-treated advanced KRAS G12D mutant solid tumors, and started enrolling patients for a combination cohort with cetuximab. These results highlight Verastem’s potential first-mover advantage in targeting KRAS G12D mutations, an area with no currently approved FDA therapies. We’ll explore how the progress in targeting... Oct 25, 2025 - $VSTM
Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Verastem (VSTM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. Oct 23, 2025 - $VSTM
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
BOSTON, October 23, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2025 financial results and business updates on Tuesday, November 4, 2025, at 8:00 am ET. Oct 23, 2025 - $VSTM
Verastem Oncology (VSTM): Assessing Valuation Following Promising KRAS G12D Pancreatic Cancer Trial Update
Verastem (VSTM) is back in focus after announcing updated results from GenFleet Therapeutics’ Phase 1/2 study for GFH375, their KRAS G12D inhibitor, in advanced pancreatic cancer. These findings are important given the current lack of FDA-approved treatments for this genetic mutation. See our latest analysis for Verastem. Momentum has been building for Verastem, with the latest clinical update adding fuel to the story. The share price has jumped 49% over the last 90 days, and Verastem's... Oct 22, 2025 - $VSTM
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple